{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:30:21Z","timestamp":1786710621357,"version":"build-2736575974"},"reference-count":22,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA245871"],"award-info":[{"award-number":["CA245871"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Homozygous deletion of the methylthioadenosine phosphorylase (MTAP) gene is a frequent genetic alteration in cancer. The MTAP enzyme, which creates adenine from 5\u2032-methylthioadenosine (MTA), is constitutively expressed in all tissues throughout the body. Previously, we described a novel strategy to specifically target MTAP-deleted cancer cells by combining the antipurine prodrug 2-fluoroadenine (2FA) with MTA. In vitro, this combination efficiently kills MTAP\u2212 cancer cells while leaving MTAP+ cells unharmed. However, in vivo, the combination was less effective at tumor cell killing, resulting in slower growth but not tumor regression. In this study, we show that this effectiveness difference is associated with a large difference in the amount of 2FA that is incorporated into 2FA-containing nucleotides. To explain this observation, we tested the hypothesis that 2FA was a target for the purine metabolic enzyme xanthine oxidase (XO), which is found in various extracellular fluids. In vitro, the addition of XO protein to culture media effectively abolishes killing by 2FA, and this effect can be fully reversed by the addition of febuxostat (FX), a XO inhibitor. In vivo, the addition of FX to 2FA results in increased cell killing and toxicity, and a 1,000% increase in the amount of 2FA that is converted to its active form, 2FA-monophosphate. Xenograft studies using MTAP\u2212 HT1080 and MiaPaCa-2 cell lines show that a 2FA\/MTA\/FX cocktail can cause tumor regression in vivo. These studies suggest that a combination of 2FA\/MTA\/FX may be useful in treating MTAP\u2212 cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Deletion of the MTAP gene is one of the most frequent genetic alterations in cancer, making it a potentially good target for cancer therapy. Previously, we demonstrated that a combination of 2FA and MTA could specifically target MTAP\u2212 cells. In this study, we show that the addition of FX substantially increases the potency of 2FA\/MTA in vivo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0193","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:36:06Z","timestamp":1785486966000},"page":"1933-1942","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Febuxostat Enhances the Antitumor Efficacy of 2-Fluoroadenine and 5\u2032-Methylthioadenosine in\n                    <i>MTAP<\/i>\n                    -Deleted Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4117-6258","authenticated-orcid":false,"given":"Baiqing","family":"Tang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5143-8667","authenticated-orcid":false,"given":"Hyung-Ok","family":"Lee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3399-9857","authenticated-orcid":false,"given":"Daniel","family":"Krzizike","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 2 Cancer Prevention and Control Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6034-3377","authenticated-orcid":false,"given":"Kathy Q.","family":"Cai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7030-8792","authenticated-orcid":false,"given":"Sapna","family":"Gupta","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4990-3695","authenticated-orcid":false,"given":"Warren D.","family":"Kruger","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0567t7073","id-type":"ROR","asserted-by":"publisher"}],"name":"Fox Chase Cancer Center 1 Cancer Signaling and Microenvironment Program, , Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"2026081407103811400_bib1","doi-asserted-by":"publisher","first-page":"D1153","DOI":"10.1093\/nar\/gkz974","article-title":"ProteomicsDB: a multi-omics and multi-organism resource for life science research","volume":"48","author":"Samaras","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2026081407103811400_bib2","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1073\/pnas.81.9.2665","article-title":"Assignment of the gene for methylthioadenosine phosphorylase to human chromosome 9 by mouse-human somatic cell hybridization","volume":"81","author":"Carrera","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026081407103811400_bib3","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0888-7543(05)80238-1","article-title":"Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia","volume":"14","author":"Olopade","year":"1992","journal-title":"Genomics"},{"key":"2026081407103811400_bib4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","journal-title":"Nature"},{"key":"2026081407103811400_bib5","doi-asserted-by":"publisher","first-page":"100966","DOI":"10.1016\/j.ctarc.2025.100966","article-title":"A systematic literature review of MTAP deletions in solid and hematologic cancers","volume":"44","author":"Clouser","year":"2025","journal-title":"Cancer Treat Res Commun"},{"key":"2026081407103811400_bib6","doi-asserted-by":"publisher","first-page":"1173356","DOI":"10.3389\/fcell.2023.1173356","article-title":"Methylthioadenosine phosphorylase deficiency in tumors: a compelling therapeutic target","volume":"11","author":"Fan","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"2026081407103811400_bib7","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1158\/0008-5472.CAN-18-0814","article-title":"Specific targeting of MTAP-deleted tumors with a combination of 2\u2032-fluoroadenine and 5\u2032-methylthioadenosine","volume":"78","author":"Tang","year":"2018","journal-title":"Cancer Res"},{"key":"2026081407103811400_bib8","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/s0006-2952(98)00034-3","article-title":"Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells","volume":"55","author":"Parker","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"2026081407103811400_bib9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.4161\/cbt.21115","article-title":"Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells","volume":"13","author":"Tang","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"2026081407103811400_bib10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ccell.2020.08.015","article-title":"Cholesterol pathway inhibition induces TGF-beta signaling to promote basal differentiation in pancreatic cancer","volume":"38","author":"Gabitova-Cornell","year":"2020","journal-title":"Cancer Cell"},{"key":"2026081407103811400_bib11","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1158\/0008-5472.CAN-06-3752","article-title":"K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling","volume":"67","author":"Campbell","year":"2007","journal-title":"Cancer Res"},{"key":"2026081407103811400_bib12","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.3791\/2573","article-title":"Clonogenic assay: adherent cells","author":"Rafehi","year":"2011","journal-title":"J Vis Exp"},{"key":"2026081407103811400_bib13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2342-8-16","article-title":"Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper","volume":"8","author":"Jensen","year":"2008","journal-title":"BMC Med Imaging"},{"key":"2026081407103811400_bib14","doi-asserted-by":"publisher","first-page":"562","DOI":"10.52312\/jdrs.2025.1976","article-title":"The efficacy and safety of different doses of febuxostat and allopurinol: a meta-analysis","volume":"36","author":"Zhang","year":"2025","journal-title":"Jt Dis Relat Surg"},{"key":"2026081407103811400_bib15","doi-asserted-by":"publisher","first-page":"102623","DOI":"10.1016\/j.redox.2023.102623","article-title":"The clinical value of serum xanthine oxidase levels in patients with acute ischemic stroke","volume":"60","author":"Yu","year":"2023","journal-title":"Redox Biol"},{"key":"2026081407103811400_bib16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2026081407103811400_bib17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/0003-9861(57)90088-7","article-title":"8-Hydroxyadenine as the intermediate in the oxidation of adenine to 2, 8-dihydroxyadenine by xanthine oxidase","volume":"70","author":"Wyngaarden","year":"1957","journal-title":"Arch Biochem Biophys"},{"key":"2026081407103811400_bib18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/092986711793979760","article-title":"Regulation of xanthine oxidase activity by substrates at active sites via cooperative interactions between catalytic subunits: implication to drug pharmacokinetics","volume":"18","author":"Tai","year":"2011","journal-title":"Curr Med Chem"},{"key":"2026081407103811400_bib19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/s0168-8278(00)00078-7","article-title":"5\u2032-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication","volume":"34","author":"Simile","year":"2001","journal-title":"J Hepatol"},{"key":"2026081407103811400_bib20","doi-asserted-by":"publisher","first-page":"e90671","DOI":"10.1371\/journal.pone.0090671","article-title":"Differential neuroprotective effects of 5\u2032-deoxy-5\u2032-methylthioadenosine","volume":"9","author":"Moreno","year":"2014","journal-title":"PLoS One"},{"key":"2026081407103811400_bib21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejphar.2014.11.013","article-title":"The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung","volume":"746","author":"Kataoka","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"2026081407103811400_bib22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.3390\/biom15070948","article-title":"PRMT5 identified as a viable target for combination therapy in preclinical models of pancreatic cancer","volume":"15","author":"Wei","year":"2025","journal-title":"Biomolecules"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0193\/3818446\/crc-26-0193.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1933\/3821241\/crc-26-0193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1933\/3821241\/crc-26-0193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:34:30Z","timestamp":1786707270000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/1933\/787435\/Febuxostat-Enhances-the-Antitumor-Efficacy-of-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0193","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33254342","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254321","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254330","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254309","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254339","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254327","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254315","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254318","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254312","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254336","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254333","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33254324","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8654225","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}